perimenostage

Last checked September 2026 against 11 sources · Editorial policy

GLP-1 drugs and menopause

GLP-1 drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for weight loss in adults with obesity, or overweight plus a weight-related condition, including women in menopause. A 2026 Spanish Menopause Society statement says semaglutide has the most menopause-specific evidence, though it's limited and mostly observational. In one study, women also taking HRT lost 16% of body weight at 12 months vs 12% without it. GLP-1s don't treat hot flashes.

Semaglutide and tirzepatide in menopause: who qualifies, what the limited evidence shows, weight loss with HRT, protecting muscle, birth control and compounding risks.

GLP-1 drugs in menopause: expectation vs reality

What people often expect

“A GLP-1 shot will fix menopause weight gain and my other menopause symptoms”

What the evidence shows

GLP-1 drugs cause weight loss, but they're approved for weight, not menopause symptoms, and menopause-specific research is limited. Experts advise pairing them with resistance exercise and enough protein to protect muscle and bone, and say HRT shouldn't be started just to boost weight loss.

GLP-1 drugs and menopause: what the evidence shows

What GLP-1 drugs are approved for

Wegovy (semaglutide) and Zepbound (tirzepatide) are indicated, with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term in adults with obesity, or with overweight plus at least one weight-related condition. Ozempic is a semaglutide brand, and Wegovy also comes as tablets.

GLP-1 and menopause: the evidence

The Spanish Menopause Society reviewed studies up to April 2026. Semaglutide had the largest amount of direct menopause-specific evidence, but it remains limited and largely observational. Tirzepatide and other dual incretin drugs look promising, especially for heart and metabolic disease and sleep apnea, but need menopause-specific study.

GLP-1 plus HRT

In a retrospective study of postmenopausal women on semaglutide, the 16 also using hormone therapy lost 16% of body weight at 12 months, vs 12% for the 90 not using it. The Spanish Menopause Society calls this link hypothesis-generating and says HRT shouldn't be started only to increase weight loss.

Learn more →

Protecting muscle and bone on a GLP-1

Menopause already speeds up fat gain and muscle loss. Experts advise that GLP-1 treatment in menopause include resistance exercise, adequate protein, and attention to muscle health and fracture risk. The CDC recommends muscle strengthening at least 2 days a week.

Learn more →

GLP-1 side effects and warnings

Common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, fatigue and hair loss. Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents; the drugs aren't for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.

GLP-1 in perimenopause and birth control

Perimenopausal women can still get pregnant. Zepbound may reduce how well oral hormonal contraceptives work because it slows stomach emptying. The label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase.

Learn more →

Microdosing and compounded GLP-1s

The FDA warns that unapproved and compounded versions of semaglutide and tirzepatide aren't reviewed for safety, effectiveness or quality. It has received reports of hospitalizations from dosing errors and doses beyond the approved label, plus fraudulent products. Taking a 'microdose' isn't an approved regimen in the labels.

GLP-1 in menopause by the numbers

From the studies on this page

  • body weight lost at 12 months on semaglutide with vs without HRT in one study

    16% vs 12%

2.4 mg

once weekly is the usual Wegovy injection maintenance dose

2.5 mg

once weekly is the Zepbound starting dose, raised in 2.5 mg steps

4 weeks

of backup contraception is advised after starting Zepbound and after each dose increase if you use the pill

The HRT-semaglutide comparison was retrospective and included only 16 women on HRT.

How to use GLP-1 drugs safely in menopause

  • FDA-approved GLP-1 with a prescription

    Strong evidence

    Approved for long-term weight loss with obesity, or overweight plus a weight-related condition, alongside diet and activity.

  • Resistance exercise and enough protein

    Strong evidence

    Recommended alongside incretin drugs in menopause to protect muscle and bone.

    Related guide →
  • HRT for menopause symptoms

    If this is the cause

    May be linked with more weight loss on semaglutide, but start it for symptoms, not to boost weight loss.

    Related guide →
  • Non-oral contraception in perimenopause

    If this is the cause

    Switch from the pill or add a barrier method when starting or increasing Zepbound.

    Related guide →
  • Compounded or 'microdosed' GLP-1

    No good evidence

    Not FDA-reviewed for safety or quality; dosing errors have led to hospitalizations.

When to talk to a doctor about GLP-1 drugs

  • Urgent: Severe stomach pain that won't go away

    Stop the drug and get medical help right away.

  • A lump or swelling in the neck, trouble swallowing or hoarseness

    Tell your doctor; these can be thyroid tumor symptoms listed in the labels.

  • Considering a GLP-1 in menopause

    Ask whether you qualify and how to protect muscle and bone during treatment.

GLP-1 and menopause: questions women ask

Does GLP-1 help with menopause weight gain?

GLP-1 drugs cause weight loss in adults with obesity, including postmenopausal women. Menopause-specific evidence is limited and mostly observational.

Does GLP-1 help with perimenopause symptoms?

They aren't approved or proven for hot flashes or other perimenopause symptoms. Their approved use is weight management.

What is the best GLP-1 for menopause?

Semaglutide has the most menopause-specific evidence so far; tirzepatide is promising but needs menopause-specific study, according to the Spanish Menopause Society.

Can you take Ozempic or Wegovy with HRT?

Yes, they're taken together. One study found women on HRT lost more weight on semaglutide, but HRT shouldn't be started only for that reason.

Is microdosing GLP-1 safe in perimenopause?

Microdosing isn't an approved regimen. The FDA warns compounded GLP-1s aren't reviewed for safety or quality and has reports of dosing-error hospitalizations.

Does insulin resistance get worse in menopause?

Visceral fat rises after menopause, which raises diabetes risk. A meta-analysis found HRT lowered insulin resistance by 12.9% in women without diabetes.

Can GLP-1 drugs affect birth control?

Zepbound can make birth control pills less effective. Use a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase.

Does metformin help with menopause?

Metformin is a diabetes medicine, not a menopause treatment. A 2025 review said randomized trials are needed to understand its role in perimenopausal and menopausal women.

Sources

  1. Wegovy (semaglutide). US prescribing information, DailyMed.
  2. Zepbound (tirzepatide). US prescribing information, DailyMed.
  3. Sánchez-Prieto M, Romero-Domínguez M, Orozco R, et al. Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society. Maturitas. 2026;213:109101.
  4. Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266-274.
  5. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865.
  6. CDC. Adult Activity: An Overview. Physical Activity Basics.
  7. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
  8. Lovejoy JC, Champagne CM, de Jonge L, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). 2008;32(6):949-58.
  9. British Dietetic Association. Eating well for the perimenopause and menopause (food fact sheet).
  10. Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538-54.
  11. Lim BSY, Chen M, Li HY, et al. Metformin use in prediabetes: A review of evidence and a focus on metabolic features among peri-menopausal women. Diabetes Obes Metab. 2025;27 Suppl 3(Suppl 3):3-15.

See our editorial policy.

Related guides

Doctor-ready summary

Your stage in 2 minutes.

You leave with a stage estimate and a one-page summary sized for a short appointment.

Begin 2-minute stage check

Private · No app download

Sample report

Stage estimateLate transition
Sleep driving burden · TSH worth ruling out